NanoString Takes Option to Liver Cancer Gene Signature for Possible Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – NanoString Technologies today announced it has secured the option to exclusively license a 186-gene signature from the Broad Institute that may be useful in determining the prognosis of patients diagnosed with hepatocellular carcinoma, or HCC.

In addition to potentially being useful for HCC, the gene signature may also help determine the prognosis of patients with hepatitis C-related early stage cirrhosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.